CN103751611A - 一种治疗体癣的复方中药 - Google Patents
一种治疗体癣的复方中药 Download PDFInfo
- Publication number
- CN103751611A CN103751611A CN201410019800.8A CN201410019800A CN103751611A CN 103751611 A CN103751611 A CN 103751611A CN 201410019800 A CN201410019800 A CN 201410019800A CN 103751611 A CN103751611 A CN 103751611A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- herbal mixture
- tinea corporis
- treatment
- Prior art date
Links
- 239000003814 drugs Substances 0.000 title claims abstract description 48
- 206010005913 Body tinea Diseases 0.000 title claims abstract description 44
- 201000003875 tinea corporis Diseases 0.000 title claims abstract description 44
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 280000765563 Bamboo companies 0.000 claims abstract description 21
- 235000017166 Bambusa arundinacea Nutrition 0.000 claims abstract description 21
- 235000017491 Bambusa tulda Nutrition 0.000 claims abstract description 21
- 241001057584 Myrrha Species 0.000 claims abstract description 21
- 235000015334 Phyllostachys viridis Nutrition 0.000 claims abstract description 21
- 239000011425 bamboo Substances 0.000 claims abstract description 21
- 239000007788 liquids Substances 0.000 claims abstract description 19
- 238000002360 preparation methods Methods 0.000 claims abstract description 5
- 239000000203 mixtures Substances 0.000 claims description 53
- 210000003491 Skin Anatomy 0.000 claims description 30
- 206010043866 Tinea capitis Diseases 0.000 claims description 21
- 241001330002 Bambuseae Species 0.000 claims description 20
- 241000533849 Gleditsia Species 0.000 claims description 20
- 239000009636 Huang Qi Substances 0.000 claims description 20
- 208000009189 Tinea Favosa Diseases 0.000 claims description 20
- 241001071795 Gentiana Species 0.000 claims description 19
- 241000207929 Scutellaria Species 0.000 claims description 19
- 239000011248 coating agents Substances 0.000 claims description 18
- 238000000576 coating method Methods 0.000 claims description 18
- 239000011901 water Substances 0.000 claims description 9
- 239000000843 powders Substances 0.000 claims description 8
- 239000011812 mixed powders Substances 0.000 claims description 7
- 239000007921 sprays Substances 0.000 claims description 7
- 239000000052 vinegar Substances 0.000 claims description 7
- 201000004681 psoriasis Diseases 0.000 abstract description 5
- 208000005679 Eczema Diseases 0.000 abstract description 4
- 201000004624 dermatitis Diseases 0.000 abstract description 4
- 231100001003 eczema Toxicity 0.000 abstract description 4
- 231100000486 side effect Toxicity 0.000 abstract description 3
- 206010059866 Drug resistance Diseases 0.000 abstract description 2
- 239000004863 Frankincense Substances 0.000 abstract description 2
- 239000003610 charcoal Substances 0.000 abstract description 2
- 230000001225 therapeutic Effects 0.000 abstract description 2
- 229940107666 ASTRAGALUS ROOT Drugs 0.000 abstract 1
- 240000000031 Achyranthes bidentata Species 0.000 abstract 1
- 241000382455 Angelica sinensis Species 0.000 abstract 1
- 240000003917 Bambusa tulda Species 0.000 abstract 1
- 240000005855 Dictamnus albus Species 0.000 abstract 1
- 206010013663 Drug dependence Diseases 0.000 abstract 1
- 241000931143 Gleditsia sinensis Species 0.000 abstract 1
- 241000334154 Isatis tinctoria Species 0.000 abstract 1
- 241000270273 Ptyas dhumnades Species 0.000 abstract 1
- 240000004534 Scutellaria baicalensis Species 0.000 abstract 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 abstract 1
- 206010046736 Urticarias Diseases 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 239000000463 materials Substances 0.000 abstract 1
- 230000000576 supplementary Effects 0.000 abstract 1
- 210000004369 Blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 210000000214 Mouth Anatomy 0.000 description 14
- 208000003251 Pruritus Diseases 0.000 description 14
- 201000010099 diseases Diseases 0.000 description 14
- 210000000952 Spleen Anatomy 0.000 description 11
- 230000000694 effects Effects 0.000 description 9
- 230000001737 promoting Effects 0.000 description 8
- 230000017531 blood circulation Effects 0.000 description 7
- 231100000614 Poisons Toxicity 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- 208000002474 Tinea Diseases 0.000 description 5
- 241000130764 Tinea Species 0.000 description 5
- 206010000496 Acne Diseases 0.000 description 4
- 210000003734 Kidney Anatomy 0.000 description 4
- 210000004185 Liver Anatomy 0.000 description 4
- 210000004072 Lung Anatomy 0.000 description 4
- 206010025421 Macule Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 229940079593 drugs Drugs 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 230000025627 positive regulation of urine volume Effects 0.000 description 3
- 201000005404 rubella Diseases 0.000 description 3
- 239000003440 toxic substances Substances 0.000 description 3
- 206010063409 Acarodermatitis Diseases 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 208000001840 Dandruff Diseases 0.000 description 2
- 210000003414 Extremities Anatomy 0.000 description 2
- 206010060891 General symptom Diseases 0.000 description 2
- 229940088597 Hormone Drugs 0.000 description 2
- 206010022114 Injuries Diseases 0.000 description 2
- 210000003141 Lower Extremity Anatomy 0.000 description 2
- 210000003205 Muscles Anatomy 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 210000004915 Pus Anatomy 0.000 description 2
- 206010039509 Scab Diseases 0.000 description 2
- 208000005687 Scabies Diseases 0.000 description 2
- 241000447727 Scabies Species 0.000 description 2
- 206010040882 Skin lesion Diseases 0.000 description 2
- 210000002784 Stomach Anatomy 0.000 description 2
- 206010052568 Urticaria chronic Diseases 0.000 description 2
- 238000004458 analytical methods Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000003203 everyday Effects 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 239000005556 hormones Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001939 inductive effects Effects 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 230000003000 nontoxic Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000001717 pathogenic Effects 0.000 description 2
- 244000052769 pathogens Species 0.000 description 2
- 231100000444 skin lesions Toxicity 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001015 Abdomen Anatomy 0.000 description 1
- 206010049865 Achromotrichia acquired Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 208000002399 Aphthous Stomatitis Diseases 0.000 description 1
- 210000001367 Arteries Anatomy 0.000 description 1
- 206010003549 Asthenia Diseases 0.000 description 1
- 210000000988 Bone and Bones Anatomy 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N Chlorphenamine Chemical compound data:image/svg+xml;base64,<?xml version='1.0' encoding='iso-8859-1'?>
<svg version='1.1' baseProfile='full'
              xmlns='http://www.w3.org/2000/svg'
                      xmlns:rdkit='http://www.rdkit.org/xml'
                      xmlns:xlink='http://www.w3.org/1999/xlink'
                  xml:space='preserve'
width='300px' height='300px' viewBox='0 0 300 300'>
<!-- END OF HEADER -->
<rect style='opacity:1.0;fill:#FFFFFF;stroke:none' width='300' height='300' x='0' y='0'> </rect>
<path class='bond-0' d='M 80.0582,184.881 L 35.637,176.7' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-0' d='M 75.0313,174.769 L 43.9364,169.043' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-18' d='M 80.0582,184.881 L 109.354,150.501' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-1' d='M 35.637,176.7 L 20.5113,134.139' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-2' d='M 20.5113,134.139 L 49.8069,99.7598' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-2' d='M 31.7815,134.841 L 52.2884,110.776' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-3' d='M 49.8069,99.7598 L 66.4966,102.834' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-3' d='M 66.4966,102.834 L 83.1864,105.907' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-4' d='M 98.5088,119.986 L 103.931,135.243' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-4' d='M 103.931,135.243 L 109.354,150.501' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-4' d='M 91.6235,127.588 L 95.4192,138.269' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-4' d='M 95.4192,138.269 L 99.215,148.949' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-5' d='M 109.354,150.501 L 153.775,158.682' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-6' d='M 153.775,158.682 L 168.901,201.243' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-11' d='M 153.775,158.682 L 183.071,124.303' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-7' d='M 168.901,201.243 L 213.322,209.424' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-8' d='M 213.322,209.424 L 218.745,224.682' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-8' d='M 218.745,224.682 L 224.167,239.939' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-9' d='M 239.49,254.018 L 256.179,257.091' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-9' d='M 256.179,257.091 L 272.869,260.165' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-10' d='M 218.184,264.029 L 208.668,275.196' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-10' d='M 208.668,275.196 L 199.152,286.364' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-12' d='M 183.071,124.303 L 227.492,132.484' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-12' d='M 191.37,116.646 L 222.465,122.372' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-19' d='M 183.071,124.303 L 167.945,81.7423' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-13' d='M 227.492,132.484 L 256.788,98.1043' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-14' d='M 256.788,98.1043 L 241.662,55.5439' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-14' d='M 246.007,94.7454 L 235.419,64.9531' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-15' d='M 241.662,55.5439 L 251.178,44.3766' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-15' d='M 251.178,44.3766 L 260.694,33.2093' style='fill:none;fill-rule:evenodd;stroke:#5BB772;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-16' d='M 241.662,55.5439 L 197.241,47.3629' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-17' d='M 197.241,47.3629 L 167.945,81.7423' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-17' d='M 199.722,58.3789 L 179.215,82.4445' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<text dominant-baseline="central" text-anchor="start" x='89.2089' y='110.199' style='font-size:15px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;fill:#4284F4' ><tspan>N</tspan></text>
<text dominant-baseline="central" text-anchor="middle" x='228.448' y='254.243' style='font-size:15px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;fill:#4284F4' ><tspan>N</tspan></text>
<text dominant-baseline="central" text-anchor="start" x='263.932' y='23.4228' style='font-size:15px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;fill:#5BB772' ><tspan>Cl</tspan></text>
</svg>
 data:image/svg+xml;base64,<?xml version='1.0' encoding='iso-8859-1'?>
<svg version='1.1' baseProfile='full'
              xmlns='http://www.w3.org/2000/svg'
                      xmlns:rdkit='http://www.rdkit.org/xml'
                      xmlns:xlink='http://www.w3.org/1999/xlink'
                  xml:space='preserve'
width='85px' height='85px' viewBox='0 0 85 85'>
<!-- END OF HEADER -->
<rect style='opacity:1.0;fill:#FFFFFF;stroke:none' width='85' height='85' x='0' y='0'> </rect>
<path class='bond-0' d='M 22.1832,51.8829 L 9.59714,49.5649' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-0' d='M 20.7589,49.018 L 11.9486,47.3954' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-18' d='M 22.1832,51.8829 L 30.4836,42.142' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-1' d='M 9.59714,49.5649 L 5.31153,37.5061' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-2' d='M 5.31153,37.5061 L 13.6119,27.7653' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-2' d='M 8.50476,37.7051 L 14.3151,30.8865' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-3' d='M 13.6119,27.7653 L 18.9806,28.754' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-3' d='M 18.9806,28.754 L 24.3493,29.7427' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-4' d='M 26.956,32.2162 L 28.7198,37.1791' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-4' d='M 28.7198,37.1791 L 30.4836,42.142' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-4' d='M 25.0734,34.5622 L 26.308,38.0362' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-4' d='M 26.308,38.0362 L 27.5427,41.5103' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-5' d='M 30.4836,42.142 L 43.0696,44.46' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-6' d='M 43.0696,44.46 L 47.3552,56.5188' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-11' d='M 43.0696,44.46 L 51.37,34.7191' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-7' d='M 47.3552,56.5188 L 59.9413,58.8367' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-8' d='M 59.9413,58.8367 L 61.705,63.7996' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-8' d='M 61.705,63.7996 L 63.4688,68.7626' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-9' d='M 66.0756,71.236 L 71.4442,72.2247' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-9' d='M 71.4442,72.2247 L 76.8129,73.2135' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-10' d='M 62.4093,73.0285 L 59.1679,76.8324' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-10' d='M 59.1679,76.8324 L 55.9265,80.6364' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-12' d='M 51.37,34.7191 L 63.9561,37.0371' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-12' d='M 53.7215,32.5496 L 62.5318,34.1722' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-19' d='M 51.37,34.7191 L 47.0844,22.6603' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-13' d='M 63.9561,37.0371 L 72.2565,27.2962' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-14' d='M 72.2565,27.2962 L 67.9709,15.2374' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-14' d='M 69.2019,26.3445 L 66.202,17.9034' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-15' d='M 67.9709,15.2374 L 71.2123,11.4335' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-15' d='M 71.2123,11.4335 L 74.4538,7.62954' style='fill:none;fill-rule:evenodd;stroke:#5BB772;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-16' d='M 67.9709,15.2374 L 55.3848,12.9195' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-17' d='M 55.3848,12.9195 L 47.0844,22.6603' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-17' d='M 56.088,16.0407 L 50.2777,22.8593' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<text dominant-baseline="central" text-anchor="start" x='24.7758' y='30.7231' style='font-size:4px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;fill:#4284F4' ><tspan>N</tspan></text>
<text dominant-baseline="central" text-anchor="middle" x='64.2269' y='71.5354' style='font-size:4px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;fill:#4284F4' ><tspan>N</tspan></text>
<text dominant-baseline="central" text-anchor="start" x='74.2807' y='6.13647' style='font-size:4px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;fill:#5BB772' ><tspan>Cl</tspan></text>
</svg>
 C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 206010009346 Clonus Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000006111 Contracture Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010012601 Diabetes mellitus Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000668709 Dipterocarpus costatus Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000208367 Euonymus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 210000000232 Gallbladder Anatomy 0.000 description 1
- 206010018987 Haemorrhages Diseases 0.000 description 1
- 210000003128 Head Anatomy 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000006750 Hematuria Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010022437 Insomnia Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 241000321541 Leptolegnia sp. Species 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 240000008962 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 208000010195 Onychomycosis Diseases 0.000 description 1
- 101710028385 PNPT1 Proteins 0.000 description 1
- 210000002826 Placenta Anatomy 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 102100006063 Polyribonucleotide nucleotidyltransferase 1, mitochondrial Human genes 0.000 description 1
- 208000008425 Protein Deficiency Diseases 0.000 description 1
- 206010072736 Rheumatic diseases Diseases 0.000 description 1
- 206010040943 Skin ulcer Diseases 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 206010067197 Tinea manuum Diseases 0.000 description 1
- 210000003932 Urinary Bladder Anatomy 0.000 description 1
- 210000002700 Urine Anatomy 0.000 description 1
- 210000003462 Veins Anatomy 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 230000003213 activating Effects 0.000 description 1
- 239000004480 active ingredients Substances 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 201000000736 amenorrhea Diseases 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000000202 analgesic Effects 0.000 description 1
- 230000000844 anti-bacterial Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- 230000001276 controlling effects Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000002552 dosage forms Substances 0.000 description 1
- 238000005516 engineering processes Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 244000053095 fungal pathogens Species 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000001861 immunosuppresant Effects 0.000 description 1
- 239000003018 immunosuppressive agents Substances 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000000977 initiatory Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 230000003902 lesions Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 230000002175 menstrual Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 238000000034 methods Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 239000002574 poisons Substances 0.000 description 1
- 230000001047 pyretic Effects 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching Effects 0.000 description 1
- 230000001932 seasonal Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substances Substances 0.000 description 1
- 230000002522 swelling Effects 0.000 description 1
- 201000010874 syndrome Diseases 0.000 description 1
- 201000010618 tinea cruris Diseases 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 201000005882 tinea unguium Diseases 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Abstract
Description
一种治疗体癣的复方中药
技术领域
[0001] 本发明涉及一种治疗体癣的复方中药。
背景技术 [0002] 体癣常由自身接种传染而引起,凡致病性真菌寄生在人体的光滑皮肤上所引起的浅表损害统称为体癣。古医籍称之为圆癣、钱癣,本病西医也称为体癣。也就是说先发生手癣、脚癣、股癣、甲癣或头癣,然后由这些癣病再传染到皮肤上来,单独的体癣较少见。当然,如果与癣病患者密切接触或共用毛巾、衣裤等也可以被传染。另外,癣病的发生与机体抵抗力强弱有关。当患有糖尿病或其他全身性疾病以及长期大量应用激素、免疫抑制剂等都会使机体免疫力下降,这时即使真菌数量很少也能引起体癣。初发时为小的丘疹,逐渐向外扩大,中心有自行愈合的倾向,呈圆形或多环形,在四周有丘疹,水疱,结痂或鳞屑组成的高出于皮面的环状边缘,境界清楚,多发生于面、颈、躯干和四肢等处,自觉搔痒。目前对体癣的治疗还没有一种行之有效的治疗方法,或者药物。在西医治疗方面,多采用化学制剂,如激素类药物,虽然但是见效快,但副作用大,且容易复发;而现有中药制剂需要较长的治疗周期,并且费用高,虽有一定的疗效,但起不到根本的治疗作用,给患者带来精神上和经济上带来沉重的负担。
发明内容
[0003] 本发明要解决的技术问题是如何克服现有技术的上述缺陷,提供一种治疗体癣的复方中药。
[0004] 为解决上述技术问题,本治疗体癣的复方中药由以下组分按照所示重量份比例范围配制而成,龙胆草14~19份、当归11~15份、地肤子9~10份、乳香15~18份、白癣皮9~13份、生黄芪25~30份、大青叶19~23份、没药12~18份、黄芩13~17份、牛膝3~8份、竹炭10~13份、皂荚8~12份、蒲公英15~20份、乌蛇3~9份。
[0005] 作为优选配比范围,所述复方中药由以下组分按照所示重量份比例范围配制而成,龙胆草15~17份、当归12~14份、地肤子9~10份、乳香16~18份、白癣皮9~11份、生黄芪26~28份、大青叶19~21份、没药14~16份、黄芩13~15份、牛膝5~7份、竹炭11~13份、皂荚8~10份、蒲公英17~19份、乌蛇5~7份。
[0006] 作为具体优选配比,所述复方中药由以下组分按照所示重量份比例配制而成,龙胆草19份、当归11份、地肤子10份、乳香15份、白癣皮13份、生黄芪25份、大青叶23份、没药12份、黄芩17份、牛膝3份、竹炭13份、皂荚8份、蒲公英20份、乌蛇3份。
[0007] 作为具体优选配比,所述复方中药由以下组分按照所示重量份比例配制而成,龙胆草14份、当归15份、地肤子9份、乳香18份、白癖皮9份、生黄苗30份、大青叶19份、没药18份、黄芩13份、牛膝8份、竹炭10份、皂荚12份、蒲公英15份、乌蛇9份。
[0008] 作为最佳配比,所述复方中药由以下组分按照所示重量份比例配制而成,龙胆草16份、当归13份、地肤子10份、乳香17份、白癣皮10份、生黄芪27份、大青叶20份、没药15份、黄芩14份、牛膝6份、竹炭12份、皂荚9份、蒲公英18份、乌蛇6份。
[0009] 作为具体优选配比,所述复方中药由以下组分按照所示重量份比例配制而成,龙胆草17份、当归12份、地肤子10份、乳香16份、白癣皮11份、生黄芪26份、大青叶21份、没药14份、黄芩15份、牛膝5份、竹炭13份、皂荚8份、蒲公英19份、乌蛇5份。
[0010] 作为具体优选配比,所述复方中药由以下组分按照所示重量份比例配制而成,龙胆草15份、当归14份、地肤子9份、乳香18份、白癣皮9份、生黄芪28份、大青叶19份、没药16份、黄芩13份、牛膝7份、竹炭11份、皂荚10份、蒲公英17份、乌蛇7份。
[0011] 本治疗体癣的复方中药的剂型为外敷散剂的制备方法为,首先按上述重量份取各组分,将各组分混合,在混合物上喷醋后干炒,将炒干的药物暴晒24h后,研成细粉,过200目筛,以按重量比1:1的比例向筛得的混合粉末中加水,搅拌均匀,即得本治疗体癣的复方中药外涂药液。
[0012] 药理分析
[0013] 龙胆草:味甘,性温;归心、脾经。功能主治:益心脾,补气血,安神。治虚劳羸弱,失眠,健忘,惊t季,怔忡。
[0014] 当归:味甘、辛,性温;归肝、心、脾经;补血活血,调经止痛,润肠通便,活血通经。
[0015] 地肤子:味辛、苦,性寒;归肾、膀胱经;清热利湿,祛风止痒,用于小便涩痛,阴痒带下,风疹,湿疹,皮肤瘙痒。。
[0016] 乳香:味辛、苦,性温;活血止痛,用于心腹诸痛,筋脉拘挛,跌打损伤,疮痈肿痛,外用消肿生肌。
[0017] 白癣皮:味苦,性寒;归脾、胃经;清热燥湿,祛风解毒,用于湿热疮毒,黄水淋漓,湿疹,风疹,疥癣疮瘌,风湿热痹,黄疸`尿赤。。
[0018] 生黄芪:味甘,性温。归肺、脾经。功能主治:补气固表,利尿托毒,排脓,敛疮生肌。
[0019] 大青叶:味苦,性大寒,无毒;归肝、脾二经;清热,解毒,凉血,止血,疗时气头痛,大热,口疮。
[0020] 没药:味苦、辛,性温,无毒;归肝、脾、心、肾经;散血消肿,定痛生肌。
[0021] 黄芩:味苦,性寒,归肺、胆、脾、大肠、小肠经;具有清热燥湿、泻火解毒、止血和安胎等功效;临床应用表明黄芩抗菌效果比黄连还好,而且不产生抗药性。
[0022] 牛膝:味甘、微苦,性平。归肝、肾经。逐瘀通经,通利关节,利尿通淋。用于经闭症瘕,胞衣不下,关节痹痛,足痿筋挛,尿血血淋,跌扑损伤。
[0023] 竹炭:味苦、涩,性温;活血化瘀,健脾消食。
[0024] 皂荚:味辛、咸,性温,有毒;归肺、大肠经;祛痰止咳,开窍通闭,杀虫散结。
[0025] 蒲公英:味甘、微苦,性寒;归脾、胃、肾三经;清热解毒,消痈散结。
[0026] 乌蛇:味甘,性平,有小毒;归肺、脾二经;祛风湿,通经络,治风湿顽痹,肌肤不仁,骨、关节结核,风疹疥癣,麻风,破伤风,小儿麻痹症。
[0027] 本发明一种治疗体癣的复方中药价格低廉、疗效确切,通过药效成分与辅佐成分的各组分的合理配伍、功效相互补充和协调,具有疗程短,见效快,疗效好等优点,且为纯天然生药配伍,不会产生副作用、依赖性和抗药性,本发明还提供了该治疗体癣的复方中药外涂药液的制备方法,广泛适用于各种病因引起的体癣,尤其适用于牛皮癣、湿疹和风团等。具体实施方式
[0028] 实施例1:首先按龙胆草19份、当归11份、地肤子10份、乳香15份、白癣皮13份、生黄芪25份、大青叶23份、没药12份、黄芩17份、牛膝3份、竹炭13份、皂荚8份、蒲公英20份、乌蛇3份取各组分;将各组分混合,在混合物上喷醋后干炒,将炒干的药物暴晒24h后,研成细粉,过200目筛,以按重量比1:1的比例向筛得的混合粉末中加水,搅拌均匀,即得本治疗体癣的复方中药外涂药液A。
[0029] 实施例2:首先按龙胆草14份、当归15份、地肤子9份、乳香18份、白癣皮9份、生黄芪30份、大青叶19份、没药18份、黄芩13份、牛膝8份、竹炭10份、皂荚12份、蒲公英15份、乌蛇9份取各组分;将各组分混合,在混合物上喷醋后干炒,将炒干的药物暴晒24h后,研成细粉,过200目筛,以按重量比1:1的比例向筛得的混合粉末中加水,搅拌均匀,即得本治疗体癣的复方中药外涂药液B。
[0030] 实施例3:首先按龙胆草16份、当归13份、地肤子10份、乳香17份、白癣皮10份、生黄芪27份、大青叶20份、没药15份、黄芩14份、牛膝6份、竹炭12份、皂荚9份、蒲公英18份、乌蛇6份取各组分;将各组分混合,在混合物上喷醋后干炒,将炒干的药物暴晒24h后,研成细粉,过200目筛,以按重量比1:1的比例向筛得的混合粉末中加水,搅拌均匀,即得本治疗体癣的复方中药外涂药液C。
[0031] 实施例4:首先按龙胆草17份、当归12份、地肤子10份、乳香16份、白癣皮11份、生黄芪26份、大青叶21份、没药14份、黄芩15份、牛膝5份、竹炭13份、皂荚8份、蒲公英19份、乌蛇5份取各组分;将各组分混合,在混合物上喷醋后干炒,将炒干的药物暴晒24h后,研成细粉,过200目筛,以按重量比1:1的比例向筛得的混合粉末中加水,搅拌均匀,即得本治疗体癣的复方中药外涂药液D。
[0032] 实施例5:首先按龙胆草15份、当归14份、地肤子9份、乳香18份、白癣皮9份、生黄芪28份、大青叶19份、没药1`6份、黄芩13份、牛膝7份、竹炭11份、皂荚10份、蒲公英17份、乌蛇7份取各组分;将各组分混合,在混合物上喷醋后干炒,将炒干的药物暴晒24h后,研成细粉,过200目筛,以按重量比1:1的比例向筛得的混合粉末中加水,搅拌均匀,即得本治疗体癣的复方中药外涂药液E。
[0033] 上述事实例中,实施例3制得的治疗体癣的复方中药外涂药液C效果最为突出,为最佳实施例。
[0034] 临床资料
[0035] 对100例治疗体癣病的患者的临床应用,情况详述如下,
[0036] ( I)病例分析:①性别:按照入组标准,共治疗体癣病患者100例,其中男性60例,女性40例;②病程:6个月~I年为15例,2年~3年为50例,3年以上为35例;③年龄组:,20~30岁35例,31~40岁5例,41~50岁20例,51~60岁30例,60岁以上10例。
[0037] (2)用药方法:涂抹,每日2~3次,每次5~6g。
[0038] (3)疗效评定:①痊愈:症状消失,彻底痊愈;②显著:治愈后I年以上未有复发;③有效:各种不同体癣病患者的病发症状显著减少;④无效:治疗前后变化不大,或一度好转,后又恢复至治疗前症状。
[0039] (4)结果:(痊愈病例+显著病例+有效病例)/100例=总有效率,总有效率达95%。[0040] 典型病例(于上述临床资料病例100例中选取)
[0041] 病例1:刘某,女,30岁,患牛皮癣七年。刚开始时是头部为小红斑,后来发展到全身,成地图状紫色皮疹,表面覆盖厚厚鳞屑,奇痒无比,她先后在多家医院治疗过,但治疗时病情没有得到控制,反而越来越严重,随着病情的加重和病史的加长,她自己也曾失去过信心,但心里又不甘放过一丝希望。涂抹实施例3制得的本治疗体癣的复方中药外涂药液C二十天左右,全身症状明显减轻,涂抹二个疗程,全部症状消失,后又根据专家的的建议巩固了一个疗程完全康复,后随访至今未见复发。
[0042] 病例2:惠某,女,今年刚19岁,却已是一名十几年的牛皮癣老患者。这对一个小女孩来说,心灵上无形压上了一块大石头。然而,大夫看了不少,药也吃了许多,可总不见彻底好转。涂抹实施例3制得的本治疗体癣的复方中药外涂药液C 一个疗程的药后,皮损就开始慢慢的变薄变暗,并且皮肤瘙痒消退。吃完一个疗程的药后,又来复诊,经医生建议继续服用了两个疗程的药后,皮损完全消除。
[0043] 病例3:沈某,男,52岁,由于受凉雨淋后而感双臂不适,随后在双肘部起大小不等的红色丘疹,顶部有白皮,继而扩大融合成片状,皮屑白而厚,自觉痒,就在当地医院检查,诊断为银屑病。使用草药约20余付,但是不对症所以效果不明显,有时反而加重,后转几处大医院,中西药都吃过,时好时坏,皮屑无大变化。根据患者的具体病情,针对性的使之活血化瘀、清热润燥而给患者用药。涂抹实施例3制得的本治疗体癣的复方中药外涂药液C两个疗程,患者就基本痊愈了。后又来复查,根据患者的康复状况而又巩固了两个疗程,在后来随访中未见复发。
[0044] 病例4:钟某,男,27岁,来就诊时,患者背部大面积白斑(几乎满背都是),患病2年,主诉由于心情着急引发,并有扩散,诊断为“背部继发性白癜风,背发大部分发白,施以加强治疗,两倍剂量涂抹实施例3制得的本治疗体癣的复方中药外涂药液C 一疗程后复诊,背部白斑已痊愈面积大2/3,大部分白发变黑,继续巩固一个疗程,病情继续好转,以后每月定期复诊,背部白斑逐渐变黑,经一年多的治疗,病人白斑已全部恢复,至今未复发。
[0045] 病例5:毕某,女,31岁,`2007年3月9日初诊。全身反复起风团,瘙痒已5年,近I周皮疹发作。每年冬春即发作,每遇冷水、冷风后尤甚,得暖后减轻。曾在当地某医院诊为慢性荨麻疹,经服西药扑尔敏、多滤平及中药桂枝汤、玉屏、风散等治疗,均不显效。一周前接触冷水后,身体遍发风团、痒剧。检查:胸背、四肢散发大小不等的淡白色风团稍隆起,部分皮疹连成片,可见抓痕、血痂。伴神疲乏力,纳减便溏,经血量少,有紫块。舌苔薄白、质淡胖,脉细弱。诊断:慢性荨麻疹急性发作。证属脾肾气虚,卫阳不足,拟益气固卫,祛寒活血消瘀法。涂抹实施例3制得的本治疗体癣的复方中药外涂药液C 一疗程后,皮疹由大变小,逐渐消失,全身症状悉除,愈后随访未再复发。
[0046] 病例6:方某,男,25岁,来就诊时,主诉2年前不明原因全身瘙痒,初起轻微,渐渐增剧,每日发作次数不定,因情绪激动,过度疲劳,饮用烟酒而诱发,晚间睡前容易发作,每次数分钟至数小时,当发作时患者常强力搔抓,直到解痒为止,曾中西药治疗,用药不详,症状加重。初诊诊断:皮肤瘙痒症。治宜清热凉血、祛风止痒,涂抹实施例3制得的本治疗体癣的复方中药外涂药液C进行针对性治疗,3天后皮肤瘙痒明显减轻,日发作次数减少。连涂32天后而痊愈,随访I年,末见复发。
[0047] 病例7:郭某,女,15岁,学生。初诊时主诉5岁起即有全身皮肤瘙痒,时轻时重,冬季加剧,夜间更甚,常常抓破皮肤直至出血,曾多方医治效差,故来求诊。查体:全身皮肤干燥,遍身抓痕血痂,表皮剥落,以下肢尤为明显。脉弦细,舌苔白薄。证属血虚化燥生风。治宜养血、活血、润燥之剂,涂抹实施例3制得的本治疗体癣的复方中药外涂药液C15天后症状完全消失,病告痊愈。但过3个月后又复发,再接原方涂抹两个疗程后全愈。随访I年半未见复发。
[0048] 病例8:沙某,男,28岁,皮疹开始为成群针头大小的红色丘疹或丘疱疹,逐渐向四周扩展,形成大小不等的环状损害,边缘清楚。涂抹实施例3制得的本治疗体癣的复方中药外涂药液ClO天后症状完全消失,病告痊愈。
[0049] 上述实施方式旨在举例说明本发明可为本领域专业技术人员实现或使用,对上述实施方式进行修改对本领域的专业技术人员来说将是显而易见的,故本发明包括但不限于上述实施方式,任何符合本权利要求书或说明书描述,符合与本文所公开的原理和新颖性、创造性特点的方法、工 艺、产品,均落入本发明的保护范围之内。
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410019800.8A CN103751611A (zh) | 2014-01-16 | 2014-01-16 | 一种治疗体癣的复方中药 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410019800.8A CN103751611A (zh) | 2014-01-16 | 2014-01-16 | 一种治疗体癣的复方中药 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103751611A true CN103751611A (zh) | 2014-04-30 |
Family
ID=50519038
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410019800.8A CN103751611A (zh) | 2014-01-16 | 2014-01-16 | 一种治疗体癣的复方中药 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103751611A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101961449A (zh) * | 2010-09-21 | 2011-02-02 | 王继尧 | 一种治疗体癣病的中药 |
CN102920955A (zh) * | 2012-12-05 | 2013-02-13 | 胡海波 | 治疗脚气的外用中药组合物、制备方法和应用 |
-
2014
- 2014-01-16 CN CN201410019800.8A patent/CN103751611A/zh not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101961449A (zh) * | 2010-09-21 | 2011-02-02 | 王继尧 | 一种治疗体癣病的中药 |
CN102920955A (zh) * | 2012-12-05 | 2013-02-13 | 胡海波 | 治疗脚气的外用中药组合物、制备方法和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101564521B (zh) | 一种治疗乳腺增生的外用膏药 | |
CN103705843B (zh) | 一种治疗胃病的药物 | |
CN102119989B (zh) | 一种治疗腰间盘突出、骨质增生、肩周炎、关节炎、颈椎病的中药胶囊 | |
CN101066303B (zh) | 治疗脑血栓、脑血管硬化和中风偏瘫的药物及其制备方法 | |
CN103520654A (zh) | 一种用于治疗膝骨关节炎的中药组合物及其制备方法 | |
CN102988657A (zh) | 一种治疗骨折及跌打损伤的膏药及其制备方法 | |
CN103705751B (zh) | 用于治疗风湿腰痛的中药组合物及其制备方法 | |
CN104667047B (zh) | 一种治疗糖尿病足的中药液 | |
CN104367911B (zh) | 治疗风湿及类风湿性关节炎的中药组合物及其制备方法 | |
CN101002908A (zh) | 一种治疗骨病的贴膏 | |
CN104083457B (zh) | 治疗气虚体弱型腰肌劳损骨科药酒的制备方法 | |
CN103690888A (zh) | 一种治疗痛风的中药水蜜丸及制备方法 | |
CN103432532A (zh) | 一种治疗乳癖的中药颗粒剂及其制备方法 | |
CN104189871A (zh) | 一种治疗骨质增生的药酒 | |
CN103393862B (zh) | 一种治疗腰腿痛的中药组合物 | |
CN101897755A (zh) | 一种调脂活血理气的中药制剂及其制备方法 | |
CN102362995A (zh) | 一种治疗急性痛风性关节炎的中药制剂及其制备方法 | |
CN104740202A (zh) | 一种治疗皮肤瘙痒的中药 | |
CN104306944A (zh) | 一种治疗静脉曲张的内服药物 | |
CN104189783A (zh) | 一种治疗口腔溃疡的中药 | |
CN104644943A (zh) | 中药组合物、含该组合物的药灸及制备方法 | |
CN104258278B (zh) | 骨伤灵喷雾剂 | |
CN102488875B (zh) | 治疗继发性痛经的中药 | |
CN102247497A (zh) | 一种治疗类风湿性关节炎的中成药 | |
CN102309723A (zh) | 一种治疗关节疼痛的中药组合物及其药膏的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
C06 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
C10 | Entry into substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140430 |
|
RJ01 | Rejection of invention patent application after publication |